CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 111 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q1 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $66,000 | -93.5% | 398,945 | -90.1% | 0.00% | -100.0% |
| Q2 2022 | $1,016,000 | -74.5% | 4,029,171 | -46.3% | 0.00% | -25.0% |
| Q1 2022 | $3,992,000 | +59.3% | 7,509,908 | +84.5% | 0.00% | -20.0% |
| Q4 2021 | $2,506,000 | -38.6% | 4,070,006 | +1.7% | 0.01% | -50.0% |
| Q3 2021 | $4,081,000 | -54.4% | 4,000,237 | -18.2% | 0.01% | -60.0% |
| Q2 2021 | $8,948,000 | +33.7% | 4,889,571 | +44.0% | 0.02% | +8.7% |
| Q1 2021 | $6,691,000 | +161.1% | 3,396,393 | +65.7% | 0.02% | +130.0% |
| Q4 2020 | $2,563,000 | +61.9% | 2,050,102 | +133.1% | 0.01% | +25.0% |
| Q3 2020 | $1,583,000 | -74.4% | 879,595 | +19.5% | 0.01% | -78.4% |
| Q2 2020 | $6,177,000 | +76.9% | 736,288 | +10.5% | 0.04% | +37.0% |
| Q1 2020 | $3,492,000 | -2.6% | 666,414 | +1.5% | 0.03% | +22.7% |
| Q4 2019 | $3,585,000 | -34.7% | 656,340 | -41.8% | 0.02% | -42.1% |
| Q3 2019 | $5,488,000 | -26.3% | 1,126,812 | +4.8% | 0.04% | -25.5% |
| Q2 2019 | $7,451,000 | – | 1,075,170 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 5,045,870 | $1,273,000 | 0.73% |
| ETF MANAGERS GROUP, LLC | 7,062,485 | $1,787,000 | 0.05% |
| Ikarian Capital, LLC | 862,527 | $217,000 | 0.04% |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | 457,209 | $115,000 | 0.02% |
| Platform Technology Partners | 33,750 | $9,000 | 0.01% |
| PINNACLE ASSOCIATES LTD | 910,006 | $230,000 | 0.01% |
| CJM Wealth Advisers, Ltd. | 30,465 | $7,683 | 0.01% |
| Mirae Asset Global Investments Co., Ltd. | 4,029,171 | $1,016,000 | 0.00% |
| Vident Investment Advisory, LLC | 267,612 | $67,000 | 0.00% |
| Aries Wealth Management | 15,400 | $4,000 | 0.00% |